|
1
|
Mavaddat N, Michailidou K, Dennis J, Lush
M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, et al:
Polygenic risk scores for prediction of breast cancer and breast
cancer subtypes. Am J Hum Genet. 104:21–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Shi J, Wu L, Zheng W, Wen W, Wang S, Shu
X, Long J, Shen CY, Wu PE, Saloustros E, et al: Genetic evidence
for the association between schizophrenia and breast cancer. J
Psychiatry Brain Sci. 3(7)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
den Bossche JV: Lipid-laden macrophages
cross the border to cancer. Immunometabolism. 2(e200006)2020.
|
|
4
|
Sudharshan PJ, Petitjean C, Spanhol F,
Oliveira LE, Heutte L and Honeine P: Multiple instance learning for
histopathological breast cancer image classification. Exp Syst
Appl. 117:103–111. 2019.
|
|
5
|
Sachs N, de Ligt J, Kopper O, Gogola E,
Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H,
et al: A living biobank of breast cancer organoids captures disease
heterogeneity. Cell. 172:373–386.e10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Turner NC, Slamon DJ, Ro J, Bondarenko I,
Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, et al:
Overall survival with palbociclib and fulvestrant in advanced
breast cancer. N Engl J Med. 379:1926–1936. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang X, Qi Y, Kong X, Zhai J, Li Y, Song
Y, Wang J, Feng X and Fang Y: Immunological therapy: A novel
thriving area for triple-negative breast cancer treatment. Cancer
Lett. 442:409–428. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang X, Song W, Zhou Y, Mao F, Lin Y,
Guan J and Sun Q: Expression and function of MutT homolog 1 in
distinct subtypes of breast cancer. Oncol Lett. 13:2161–2168.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Toi M, Tanaka S, Bando M, Hayashi K and
Tominaga T: Outcome of surgical resection for chest wall recurrence
in breast cancer patients. J Surg Oncol. 64:23–26. 1997.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Waks AG and Winer EP: Breast cancer
treatment: A review. JAMA. 321:288–300. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Maxwell T, Lee KS, Kim S and Nam KS:
Arctigenin inhibits the activation of the mTOR pathway, resulting
in autophagic cell death and decreased ER expression in ER-positive
human breast cancer cells. Int J Oncol. 52:1339–1349.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Huang Q, Qin S, Yuan X, Zhang L, Ji J, Liu
X, Ma W, Zhang Y, Liu P, Sun Z, et al: Arctigenin inhibits
triple-negative breast cancers by targeting CIP2A to reactivate
protein phosphatase 2A. Oncol Rep. 38:598–606. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang M, Cai S, Zuo B, Gong W, Tang Z,
Zhou D, Weng M, Qin Y, Wang S, Liu J, et al: Arctigenin induced
gallbladder cancer senescence through modulating epidermal growth
factor receptor pathway. Tumour Biol.
39(1010428317698359)2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ke N, Liu Q, Pi L, Fang J, Chen L and Chen
X: The antitumor function of arctigenin in human retinoblastoma
cells is mediated by jagged-1. Mol Med Rep. 19:3642–3648.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xu Y, Lou Z and Lee SH: Arctigenin
represses TGF-β-induced epithelial mesenchymal transition in human
lung cancer cells. Biochem Biophys Res Commun. 493:934–939.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang P, Diaz T, Henning S and Vadgama J:
Abstract 5253: Arctigenin inhibits prostate tumor growth in vitro
and in vivo in obese state. Cancer Res. 77 (Suppl
13)(S5253)2017.
|
|
17
|
Wang Y, Lina L, Xu L, Yang Z, Qian Z, Zhou
J and Suoni L: Arctigenin enhances the sensitivity of cisplatin
resistant colorectal cancer cell by activating autophagy. Biochem
Biophys Res Commun. 520:20–26. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lou C, Zhu Z, Zhao Y, Zhu R and Zhao H:
Arctigenin, a lignan from Arctium lappa L., inhibits
metastasis of human breast cancer cells through the downregulation
of MMP-2/-9 and heparanase in MDA-MB-231 cells. Oncol Rep.
37:179–184. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Feng T, Cao W, Shen W, Zhang L, Gu X, Guo
Y, Tsai HI, Liu X, Li J, Zhang J, et al: Arctigenin inhibits STAT3
and exhibits anticancer potential in human triple-negative breast
cancer therapy. Oncotarget. 8:329–344. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhang T, Guo J, Li H and Wang J:
Meta-analysis of the prognostic value of p-4EBP1 in human
malignancies. Oncotarget. 9:2761–2769. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang Z, Feng X, Molinolo AA, Martin D,
Vitale-Cross L, Nohata N, Ando M, Wahba A, Amornphimoltham P, Wu X,
et al: 4E-BP1 Is a tumor suppressor protein reactivated by mTOR
inhibition in head and neck cancer. Cancer Res. 79:1438–1450.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Alabdullah ML, Ahmad DA, Moseley P,
Madhusudan S, Chan S and Rakha E: The mTOR downstream regulator
(p-4EBP1) is a novel independent prognostic marker in ovarian
cancer. J Obstet Gynaecol. 39:522–528. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rutkovsky AC, Yeh ES, Guest ST, Findlay
VJ, Muise-Helmericks RC, Armeson K and Ethier SP: Eukaryotic
initiation factor 4E-binding protein as an oncogene in breast
cancer. BMC Cancer. 19(491)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cristina A, Bartolacci C, Wijnant K,
Crinelli R, Bianchi M, Magnani M, Hysi A, Iezzi M, Amici A and
Marchini C: Resveratrol fuels HER2 and ERα-positive breast cancer
behaving as proteasome inhibitor. Aging (Albany NY). 9:508–520.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yoon SB and Park HR: Arctigenin inhibits
etoposide resistance in HT-29 colon cancer cells during
microenvironmental stress. J Microbiol Biotechnol. 29:571–576.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Maheshwari M, Jia Q and Valeriote FA:
Arctin and arctigenin as a potential treatment for solid tumors.
Cancer Res. 79 (Suppl 13)(S366)2019.
|
|
29
|
Naoe A, Tsuchiya T, Kondo Y, Uga N,
Watanabe S, Yasui T, Hara F and Suzuki T: Arctigenin induces
apoptosis in human hepatoblastoma cells. Pediatr Surg Int.
35:723–728. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sun Y, Tan YJ, Lu ZZ, Li BB, Sun CH, Li T,
Zhao LL, Liu Z, Zhang GM, Yao JC and Li J: Arctigenin inhibits
liver cancer tumorigenesis by inhibiting gankyrin expression via
C/EBPα and PPARα. Front Pharmacol. 9(268)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lin CY, Hsieh PL, Liao YW, Peng CY, Yu CC
and Lu MY: Arctigenin reduces myofibroblast activities in oral
submucous fibrosis by LINC00974 inhibition. Int J Mol Sci.
20(1328)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
He Y, Fan Q, Cai T, Huang W, Xie X, Wen Y
and Shi Z: Molecular mechanisms of the action of arctigenin in
cancer. Biomed Pharmacother. 108:403–407. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Maxwell T, Chun SY, Lee KS, Kim S and Nam
KS: The anti-metastatic effects of the phytoestrogen arctigenin on
human breast cancer cell lines regardless of the status of ER
expression. Int J Oncol. 50:727–735. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lee J, Imm JY and Lee SH: β-catenin
mediates anti-adipogenic and anticancer effects of arctigenin in
preadipocytes and breast cancer cells. J Agric Food Chem.
65:2513–2520. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lu Z, Chang L, Zhou H, Liu X, Li Y, Mi T
and Tong D: Arctigenin attenuates tumor metastasis through
inhibiting epithelial-mesenchymal transition in hepatocellular
carcinoma via suppressing GSK3β-dependent Wnt/β-catenin signaling
pathway in vivo and in vitro. Front Pharmacol.
10(937)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wang H, Huang F, Zhang Z, Wang P, Luo Y,
Li H, Li N, Wang J, Zhou J, Wang Y and Li S: Feedback activation of
SGK3 and AKT contributes to rapamycin resistance by reactivating
mTORC1/4EBP1 axis via TSC2 in breast cancer. Int J Biol Sci.
15:929–941. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ding M, Van der Kwast TH, Vellanki RN,
Foltz WD, McKee TD, Sonenberg N, Pandolfi PP, Koritzinsky M and
Wouters BG: The mTOR targets 4E-BP1/2 restrain tumor growth and
promote hypoxia tolerance in PTEN-driven prostate cancer. Mol
Cancer Res. 16:682–695. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Elia A, Henry-Grant R, Adiseshiah C,
Marboeuf C, Buckley RJ, Clemens MJ, Mudan S and Pyronnet S:
Implication of 4E-BP1 protein dephosphorylation and accumulation in
pancreatic cancer cell death induced by combined gemcitabine and
TRAIL. Cell Death Dis. 8(3204)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Loibl S, Darb-Esfahani S, Huober J,
Klimowicz A, Furlanetto J, Lederer B, Hartmann A, Eidtmann H,
Pfitzner B, Fasching PA, et al: Integrated analysis of PTEN and
p4EBP1 protein expression as predictors for pCR in HER2-positive
breast cancer. Clin Cancer Res. 22:2675–2683. 2016.PubMed/NCBI View Article : Google Scholar
|
